Needham raised the firm’s price target on AtriCure (ATRC) to $51 from $40 and keeps a Buy rating on the shares. The company has a strong product cycle that should drive strong growth and more than offset competitive headwinds during 2025, the analyst tells investors in a research note. AtriCure shares also remain at an attractive valuation at 3.6-times its expected 2025 sales vs. its small/mid-cap growth peers at 4.1-times, the firm added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.81M
- AtriCure reports preliminary Q4 revenue $124.3M, consensus $119.85M
- AtriCure ups FY24 revenue view to $465.3M from $459M-$462M, consensus $460.89M
- AtriCure Projects Strong Revenue Growth for 2024
- AtriCure assumed with an Overweight at JPMorgan